Chronic eosinophilic leukemia
diseaseOn this page
Also known as CELCEL/hypereosinophilic syndromeCELNOSchronic eosinophilic leukemia/hypereosinophilic syndromeeosinophilic leukaemiaeosinophilic leukemia
Summary
Chronic eosinophilic leukemia (MONDO:0015687) is a cancer and 22 clinical trials. Top therapeutic interventions include foscarnet, imatinib, and beclomethasone dipropionate. A subtype of chronic leukemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 22
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | chronic eosinophilic leukemia |
| Mondo ID | MONDO:0015687 |
| MeSH | C580364 |
| Orphanet | 168940 |
| DOID | DOID:0080367 |
| NCIT | C4563 |
| SNOMED CT | 188733003 |
| UMLS | C0346421 |
| MedGen | 91106 |
| GARD | 0020104 |
| MedDRA | 10065854 |
| Is cancer (heuristic) | yes |
Also known as: CEL · CEL/hypereosinophilic syndrome · CELNOS · chronic eosinophilic leukemia · chronic eosinophilic leukemia/hypereosinophilic syndrome · eosinophilic leukaemia · eosinophilic leukemia
Data availability: 4 cell lines.
Disease family
This is a subtype of chronic leukemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › leukemia › chronic leukemia › chronic eosinophilic leukemia
Related subtypes (7): prolymphocytic leukemia, chronic monocytic leukemia, B-cell chronic lymphocytic leukemia, chronic neutrophilic leukemia, T-cell large granular lymphocyte leukemia, aggressive NK-cell leukemia, chronic myelomonocytic leukemia
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 22.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 7 |
| Not specified | 7 |
| PHASE1 | 6 |
| PHASE3 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00799461 | PHASE3 | COMPLETED | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications |
| NCT01305200 | PHASE3 | COMPLETED | Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant |
| NCT00276926 | PHASE2 | UNKNOWN | Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias |
| NCT00381550 | PHASE2 | COMPLETED | 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia |
| NCT00489203 | PHASE2 | COMPLETED | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer |
| NCT00787384 | PHASE2 | COMPLETED | Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes |
| NCT00795769 | PHASE2 | COMPLETED | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant |
| NCT01159067 | PHASE2 | TERMINATED | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload |
| NCT01384513 | PHASE2 | COMPLETED | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies |
| NCT00025415 | PHASE1 | COMPLETED | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
| NCT00357305 | PHASE1 | COMPLETED | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders |
| NCT00890747 | PHASE1 | COMPLETED | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
| NCT01231919 | PHASE1 | COMPLETED | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia |
| NCT01484015 | PHASE1 | COMPLETED | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia |
| NCT01588015 | PHASE1 | COMPLETED | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant |
| NCT01199562 | Not specified | ACTIVE_NOT_RECRUITING | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant |
| NCT00112593 | Not specified | COMPLETED | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
| NCT00408681 | Not specified | COMPLETED | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant |
| NCT00856388 | Not specified | COMPLETED | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders |
| NCT01053494 | Not specified | COMPLETED | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer |
| NCT01233921 | Not specified | COMPLETED | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer |
| NCT01558778 | Not specified | WITHDRAWN | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FOSCARNET | 4 | 4 |
| IMATINIB | 4 | 2 |
| BECLOMETHASONE DIPROPIONATE | 4 | 1 |
| CEFEPIME HYDROCHLORIDE | 4 | 1 |
| DEFERASIROX | 4 | 1 |
| GANCICLOVIR | 4 | 1 |
| LITHIUM CARBONATE | 4 | 1 |
| PALIFERMIN | 4 | 1 |
| VALGANCICLOVIR | 4 | 1 |
| TRIAPINE | 3 | 1 |
| CHEMBL1319520 | 0 | 1 |
| CHEMBL1201736 | 0 | 1 |